OpenBit ResearchOpenBit
中文

What's driving Moderna (MRNA)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Merck-Moderna Personalized Cancer Vaccine Translation

Why it matters now

The personalized cancer vaccine program is a direct clinical and commercialization asset for Moderna, with late-stage efficacy serving as a key validation channel.

Next checkpoint

MRK earnings (expected 2026-10-29)

This is a MRK event, linked to MRNA through a shared driver. The engine does not explain how it carries over to MRNA, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Overall-survival or other key secondary endpoints weaken, or broader studies stall or produce contradictory efficacy or safety data.

Research drivers

  • Merck-Moderna Personalized Cancer Vaccine Translation

    Bullish · Active · Updated

    An analyst raised the modeled probability of adjuvant-melanoma approval from 65% to 90%, further strengthening the melanoma translation case while broader tumor-type validation remains unresolved.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • William Blair expects intismeran sales in melanoma to exceed $5.4 billion for Moderna based on a 50%/50% profit share with Merck.

    Relayed by: Benzinga · Event date on record:

  • At a pre-planned interim analysis, Merck and Moderna’s investigational combination delivered statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compare

    Relayed by: Benzinga · Event date on record:

  • William Blair analyst Myles Minter raised the modeled probability of intismeran approval in adjuvant melanoma from 65% to 90%.

    Relayed by: Benzinga · Event date on record:

  • William Blair says investor debate will turn to how much the INTerpath-001 data have de-risked intismeran in other cancer settings and whether the product can be as broad as Keytruda.

    Relayed by: Benzinga · Event date on record:

  • William Blair views the data as largely de-risking intismeran’s utility in combination with pembrolizumab and says its safety profile keeps the bar for clinical uptake low.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.